Skip to content

Comparison of the effects of walking in a suggested environment and free walking for people with Chronic Obstructive Pulmonary Disease

Ecological determinants of active behavior of people with Chronic Obstructive Pulmonary Disease and effects of walkability

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-4tfwdhp
Enrollment
Unknown
Registered
2023-08-21
Start date
2023-04-29
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

This is a randomized, controlled, double-blind clinical trial. In it, 72 participants will be divided into two groups. The experimental group will receive guided walking routes on personalized and ind

Sponsors

Universidade Federal de Juiz de Fora
Lead Sponsor
Universidade Federal de Juiz de Fora
Collaborator

Eligibility

Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Individuals with a confirmed diagnosis of Chronic Obstructive Pulmonary Disease (COPD) will be studied based on the criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD); of both sexes; with the post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio being <70% and FEV1 <80% of the predicted value 29; aged over 18 years; clinically stable; without unstable cardiovascular diseases; neurological; musculoskeletal disorders and in conditions to carry out the proposed evaluations and intervention

Exclusion criteria

Exclusion criteria: Participants unable to perform or understand the study assessments due to physical or psychological impairment will be excluded from the study; primary diagnosis of a respiratory disease other than Chronic Obstructive Pulmonary Disease (COPD); in support of oxygen therapy; with orthopedic and/or neurological limitations that prevent the performance of the tests; recent hospitalization (last 3 months); cognitive impairment identified by a score of 4 or less on the Six Item Screener; or who expressed their desire to withdraw from the study

Design outcomes

Primary

MeasureTime frame
It is expected to find an improvement in the level of physical activity of 30 minutes/day compared to the control group. Physical activity will be assessed using the Actigraph GT3X accelerometer (Actigraph LLC, USA), a validated and reliable physical activity monitor for use in individuals with chronic obstructive pulmonary disease (COPD). Data collected one week before and one week after the intervention.

Secondary

MeasureTime frame
It is expected to find an improvement evidenced by the reduction of 1 point in the report of dyspnea perception according to the modified Medical Research Council scale. Data was collected one week before the intervention and one week after the intervention. This scale was previously translated, culturally adapted, and validated for the Brazilian population. This scale comprises five activities whose symptoms of dyspnea range from 0 to 4. The higher the score, the greater the symptom of dyspnea reported.;Exercise capacity: E It is expected to find an improvement in exercise capacity, as assessed by the “six-minute walk test”, by increasing at least 30 meters in the distance walked—data collected one week before the intervention and one week after the intervention.;Perceived benefits and barriers to physical activity: will be assessed by the Exercise Barriers and Benefits Scale. It is expected to find an improvement evidenced by the reduction of 2 points in the report of perception of barriers and an increase of 1 point for perception of benefit—data collected one week before the intervention and one week after the intervention.;Quality of life: Quality of life will be assessed by the specific test for respiratory diseases Saint George's Respiratory Questionnaire (SGRQ), which has already been translated, culturally adapted, and validated for the Brazilian population. It is expected to find an improvement evidenced by the reduction of 4 points in the total score of the SGRQ, data collected one week before and one week after an intervention.;Anxiety and Depression: Anxiety and depression will be measured using the Hospital Anxiety and Depression Scale (HADS). This scale was developed to estimate the prevalence of anxiety and depression in adults and is currently used in patients with chronic lung diseases. It consists of 14 items divided into two subscales: seven questions for the diagnosis of Anxiety Disorder and another seven for Depressive Disorder. It is expected

Countries

Brazil

Contacts

Public Contactcarla malaguti

Universidade Federal de Juiz de Fora

c_malaguti@yahoo.com.br+55(32)91993329

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 5, 2026